Published online Jun 28, 2018. doi: 10.3748/wjg.v24.i24.2596
Peer-review started: March 23, 2018
First decision: April 21, 2018
Revised: April 26, 2018
Accepted: May 6, 2018
Article in press: May 6, 2018
Published online: June 28, 2018
Processing time: 94 Days and 23.9 Hours
Detection, diagnosis, and surgical treatment are the key to the improvement of liver cancer treatment. However, there is little extensive analysis of the dynamic changes and prognostic value of serum microRNAs (miRNAs) in hepatocellular carcinoma (HCC) patients.
miRNAs can be used as useful biomarkers for cancer. With a very poor 5-year survival rate in HCC, markers to assess prognosis or treatment effect are equally important.
TaqMan Low Density Array was used to screen in two pooled serum samples respectively from 35 HCC and 35 normal controls, and then the screened miRNAs were validated individually by RT-qPCR in two phases. The selected miRNAs after operation and their prognostic value were also evaluated.
miR-375, miR-10a, miR-122 and miR-423 were found to be significantly higher in HCC than in controls, and tAUC for the 4-miRNA joint diagnostic panel was 0.995 (95%CI: 0.778-0.934). The four miRNAs were significantly decreased after surgical removal, but still was higher than normal controls.
The four serum miRNAs (miR-375, miR-10a, miR-122 and miR-423) could potentially serve as novel biomarkers for the diagnostic and prognostic of HCC.
This study provides an effective and non-invasive detection method for the detection of HCC, however, more samples and the early detection value should be investigated in the future study.